INTRODUCTION

MRI-guided focal laser therapy is emerging as an intermediate modality between radical treatment and active surveillance in managing low-intermediate risk prostate cancer.

AIM

To examine the safety, feasibility and oncological outcome of in-bore MRI-guided focal laser ablation (FLT) in patients with low-intermediate risk prostate cancer.

METHOD

Inclusion: 50-75 Y/O with Low-Intermediate risk prostate cancer MRI visible lesions, PSA <10, < cT3, Gleason 7< (85% Gleason 7).

In-Bore MRI with a diode laser was used for ablation.

Follow-up: PSA, IPSS, SHIM at 1,3 and 6 months then q/6 mo MRI at 3 months, MRI-guided biopsy at 6 months

Success Definition: ablated area on targeted biopsy shows no or insignificant cancer (Gleason 6 ≤ 3mm) At 6 months.

RESULTS

31 patients underwent FLT

PSA, IPSS and SHIM scores were not significantly different from baseline at 6 months. No patient developed incontinence following the procedure.

Out of 26 patients who had a follow-up biopsy at 6 months, treatment was successful in 22 (85%)

Five patients had persistent cancer in ablated areas

Four patients had de-novo cancers outside ablated areas (Gleason 6)

Five patients are still pending biopsy

Complications: 4/31 temporary IDC

4/31 macroscopic haematuria

CONCLUSIONS: MRI-guided focal laser ablation is safe with minimum morbidity and no adverse effects on continence or potency. The oncological outcome is highly encouraging with a 85% success rate. Larger scale trials with longer follow-up are needed.

REFERENCES

[Insert references here]